Oncolytics Biotech (TSE:ONC) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Oncolytics Biotech is set to showcase promising results of their immunotherapy drug, pelareorep, in treating hard-to-treat gastrointestinal cancers at the upcoming ASCO GI Symposium. The data highlights pelareorep’s ability to enhance the effectiveness of existing cancer treatments, potentially improving patient outcomes in pancreatic and anal cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
